These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

93 related items for PubMed ID: 29407535

  • 1. Change in 1-year hospitalization of overall and older patients with major depressive disorder after second-generation antipsychotics augmentation treatment.
    Lin CY, Lai TJ, Wu YH, Chen PK, Lin YF, Chien IC.
    J Affect Disord; 2018 Apr 01; 230():118-124. PubMed ID: 29407535
    [Abstract] [Full Text] [Related]

  • 2. Effectiveness of aripiprazole, olanzapine, quetiapine, and risperidone augmentation treatment for major depressive disorder: a nationwide population-based study.
    Lin CY, Tsai GE, Wang HS, Wu YH, Chiou CC, Wu VY, Lane HY.
    J Clin Psychiatry; 2014 Sep 01; 75(9):e924-31. PubMed ID: 25295435
    [Abstract] [Full Text] [Related]

  • 3. RISK OF NEW ONSET TYPE II DM IN MDD PATIENTS RECEIVING SECOND-GENERATION ANTIPSYCHOTICS TREATMENT: A NATIONWIDE COHORT STUDY.
    Lin CY, Wu YH, Wang HS, Chen PK, Lin YF, Chien IC.
    Depress Anxiety; 2016 May 01; 33(5):435-43. PubMed ID: 26990119
    [Abstract] [Full Text] [Related]

  • 4. Antipsychotic polypharmacy among elderly patients with schizophrenia and dementia during hospitalization at a Taiwanese psychiatric hospital.
    Wu YH, Lai CY, Chang YS.
    Psychogeriatrics; 2015 Mar 01; 15(1):7-13. PubMed ID: 25515355
    [Abstract] [Full Text] [Related]

  • 5. Effect of Clozapine vs Other Second-Generation Antipsychotics on Hospitalization and Seclusion: A Retrospective Mirror-Image Study in a Japanese Public Psychiatric Hospital.
    Misawa F, Suzuki T, Fujii Y.
    J Clin Psychopharmacol; 2017 Dec 01; 37(6):664-668. PubMed ID: 29045304
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Evidence on sociodemographic and clinical correlates of antidepressant combination or augmentation with second-generation antipsychotics in major depressive disorder.
    Fugger G, Bartova L, Dold M, Fabbri C, Fanelli G, Zanardi R, Kautzky A, Zohar J, Souery D, Mendlewicz J, Montgomery S, Rujescu D, Serretti A, Kasper S.
    Prog Neuropsychopharmacol Biol Psychiatry; 2022 Mar 02; 114():110480. PubMed ID: 34826558
    [Abstract] [Full Text] [Related]

  • 8. Bipolar patients treated with long-acting injectable risperidone in Taiwan: A 1-year mirror-image study using a national claims database.
    Hsieh MH, Chuang PY, Wu CS, Chang CJ, Chung PF, Tang CH.
    J Affect Disord; 2017 Aug 15; 218():327-334. PubMed ID: 28494390
    [Abstract] [Full Text] [Related]

  • 9. Comparison of second-generation antipsychotic treatment on psychiatric hospitalization in Medicaid beneficiaries with bipolar disorder.
    Jing Y, Johnston SS, Fowler R, Bates JA, Forbes RA, Hebden T.
    J Med Econ; 2011 Aug 15; 14(6):777-86. PubMed ID: 21954966
    [Abstract] [Full Text] [Related]

  • 10. Trends and factors in antipsychotic use of outpatients with anxiety disorders in Taiwan, 2005-2013: A population-based study.
    Huang CW, Chiu YW, Chen PJ, Yu NW, Tsai HJ, Chang CM.
    Psychiatry Clin Neurosci; 2019 Aug 15; 73(8):501-507. PubMed ID: 31077503
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Prevalence, treatment patterns, and stay characteristics associated with hospitalizations for major depressive disorder.
    Citrome L, Jain R, Tung A, Landsman-Blumberg PB, Kramer K, Ali S.
    J Affect Disord; 2019 Apr 15; 249():378-384. PubMed ID: 30818246
    [Abstract] [Full Text] [Related]

  • 14. Mood stabilizer augmentation in apparently "unipolar" MDD: predictors of response in the naturalistic French national EPIDEP study.
    Hantouche EG, Akiskal HS, Lancrenon S, Chatenêt-Duchêne L.
    J Affect Disord; 2005 Feb 15; 84(2-3):243-9. PubMed ID: 15708422
    [Abstract] [Full Text] [Related]

  • 15. Augmentation with atypical antipsychotics for depression: a review of evidence-based support from the medical literature.
    Wright BM, Eiland EH, Lorenz R.
    Pharmacotherapy; 2013 Mar 15; 33(3):344-59. PubMed ID: 23456734
    [Abstract] [Full Text] [Related]

  • 16. Second-generation antipsychotics in the treatment of major depressive disorder: current evidence.
    Han C, Wang SM, Kato M, Lee SJ, Patkar AA, Masand PS, Pae CU.
    Expert Rev Neurother; 2013 Jul 15; 13(7):851-70. PubMed ID: 23898855
    [Abstract] [Full Text] [Related]

  • 17. Antidepressant combination versus antidepressants plus second-generation antipsychotic augmentation in treatment-resistant unipolar depression.
    Gobbi G, Ghabrash MF, Nuñez N, Tabaka J, Di Sante J, Saint-Laurent M, Vida S, Kolivakis T, Low N, Cervantes P, Booij L, Comai S.
    Int Clin Psychopharmacol; 2018 Jan 15; 33(1):34-43. PubMed ID: 28906325
    [Abstract] [Full Text] [Related]

  • 18. Associations Between Medication Class and Subsequent Augmentation of Depression Treatment in Privately Insured US Adults.
    Ameli O, Soria-Saucedo R, Smith EG, Cabral HJ, Soley-Bori M, Kazis LE.
    J Clin Psychopharmacol; 2017 Jun 15; 37(3):323-331. PubMed ID: 28338544
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. [Prescribing patterns of antipsychotics in 13 French psychiatric hospitals].
    Bret P, Bret MC, Queuille E.
    Encephale; 2009 Apr 15; 35(2):129-38. PubMed ID: 19393381
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.